GB2544468A

GB2544468A - Liquid formulation

Info

Publication number: GB2544468A
Application number: GB1520014.0A
Authority: GB
Inventors: Pacey Michael; Tiley John
Original assignee: JAYTEE BIOSCIENCES Ltd
Current assignee: JAYTEE BIOSCIENCES Ltd
Priority date: 2015-11-12
Filing date: 2015-11-12
Publication date: 2017-05-24
Also published as: WO2017081480A1; EP3373974A1; CA3005301A1; US20180325164A1; GB201520014D0

Abstract

The present invention relates to a liquid formulation comprising cannabidiol, a stabiliser and a liquid carrier. The liquid carrier includes propylene glycol; and the stabiliser comprises a head portion and a tail portion, wherein the head portion includes one or more reducing moieties and the tail portion comprises a C3-C20 straight or branched aliphatic chain. Preferably the stabiliser is butylated hydroxyanisole (BHA) or 6-O-palmitoyl-L-ascorbic acid (also known as 6-O-AP or ascorbyl palmitate). The formulation may further comprise one or more glyceride compounds from a plant source, nicotine, a flavouring agent and/or a scent agent. Preferably the formulation is substantially free from tetrahydrocannabinol (THC). Also claimed is an e-cigarette liquid comprising the liquid formulation.

Description

Liquid Formulation

The present invention relates to liquid formulations and in particular to liquid formulations containing cannabidiol. It also relates to e-cigarette liquids (vaping liquids or vaping formulations) containing cannabidiol. E-cigarette liquids or formulations typically include nicotine in a liquid carrier comprising propylene glycol. However, it is proposed to replace some or all of the nicotine with cannabidiol.

Cannabidiol (2-[(lR, 6R)-6-isopropenyl-3-methylcyclohex-2-en-lyl]-5-pentylbenzene-l,3-diol) is one of at least 85 active cannabinoids found in cannabis. Cannabidiol (hereinafter referred to as "CBD") is considered to be a safer alternative to tetrahydrocannabinol (THC) as it produces less or no short term memory impairment in subjects. It is also considered not to generate the feelings of anxiety often associated with the use of THC.

The structure of CBD is as follows:

It will be appreciated that the two hydroxyl groups on the benzene ring may be readily oxidised. It has been found that formulations of CBD in a liquid carrier containing propylene glycol result in the discolouration of the liquid. Without wishing to be bound by theory, this is believed to be a result of the oxidation of at least one of the hydroxyl groups of the CBD molecule.

Furthermore, it is known that CBD is largely insoluble in water, but it is soluble in organic solvents, including propylene glycol.

According to a first aspect of the invention, there is provided a liquid formulation comprising cannabidiol, a stabiliser and a liquid carrier, wherein the liquid carrier includes propylene glycol, and the stabiliser comprises a head portion and a tail portion, wherein the head portion includes one or more reducing moieties and the tail portion comprises a C3-C20 straight or branched aliphatic chain.

The head portion of the stabiliser is typically a stronger reducing agent than CBD and thus is preferentially oxidised. The head portion of the stabiliser therefore acts as an anti-oxidant for the CBD formulation.

The tail portion of the stabiliser is required to ensure that the stabiliser is soluble or miscible in the formulation. The aliphatic group may be a branched or straight chain alkyl (alkane) group, a branched or straight chain alkene group or a branched or straight chain alkyne group. In embodiments in which the aliphatic chain is unsaturated, it may be mono unsaturated or polyunsaturated.

The head portion of the stabiliser may be a hydroxyl substituted 5- or 6-membered carbocyclic or heterocyclic ring. In embodiments in which the ring is a heterocyclic ring, it may contain one or more heteroatoms each independently selected from oxygen, nitrogen and sulphur. Suitably, the heteroatom is an oxygen atom.

Examples of suitable head portions include:

Ascorbic acid derivatives, such as:

Wherein R1 is a C3-C20 aliphatic tail portion, optionally coupled to the head portion via a linker moiety.

Hydroquinone derivatives, such as:

Wherein R2 and R3 are each independently selected from H, a C1-C6 alkyl group and a C3-C20 aliphatic tail portion optionally coupled to the head portion via a linker moiety, provided that at least one of R2 and R3 comprises an aliphatic tail portion.

Hydroxychromane derivatives, such as:

Wherein R4, R5, R6 and R7 are each independently selected from OH, H, and a C1-C3 alkyl group, wherein at least one of R4, R5, R6 and R7 is OH; and R8 is a C3-C20 aliphatic tail portion, optionally coupled to the head portion via a linker moiety.

Hydroxyanisole derivatives, such as:

Wherein R9 and R10 are each independently selected from H, a C1-C6 alkyl group and a C3-C20 aliphatic tail portion, optionally coupled to the head portion via a linker moiety, provided that at least one of R9 and R10 comprises an aliphatic tail portion.

Hydroxytoluene derivatives, such as:

Wherein R11 and R12 are each independently selected from H, a C1-C6 alkyl group and a C3-C20 aliphatic tail portion, optionally coupled to the head portion via a linker moiety, provided that at least one of R11 and R12 comprises an aliphatic tail portion.

Gallic acid derivatives, such as:

Wherein R13 is a C3-C20 aliphatic tail portion.

In the above examples, the linker group, where present, may be selected from -0-, -0(0)C-, -C(0)-, -N(H)C(0)- and -N(H)-. The aliphatic tail portion is suitably a branched or straight chain alkyl group containing 3 to 20, suitably 6 to 20, 7 to 20, 10 to 20 or 12 to 18 carbon atoms. A suitable stabiliser comprises an ascorbic acid derivative as shown above, wherein R1 is a C6-C20 straight or branched aliphatic chain connected to the ascorbic acid head group via a -C(O)- linker group:

Wherein R14 is a C3-C20 aliphatic tail portion. R14 may be a C3-C20 branched or straight chain alkyl group, such as for example a C6-C20 alkyl group, a C10-C20 alkyl group or a C12-C20 alkyl group. Thus, the stabiliser may be an ascorbate ester of a long chain fatty acid having from 6 to 20 carbon atoms, 7 to 20 carbon atoms, 8 to 18 carbon atoms or 10 to 16 carbon atoms. The long chain fatty acid may be unsaturated, monounsaturated or polyunsaturated. For example, the stabiliser may be an ascorbyl ester of palmitic acid, which has a chain comprising 16 carbon atoms.

As the formulation is intended for human consumption, suitably in the form of an e-cigarette formulation, the stabiliser may already be approved for human consumption and/or as an approved food additive. For example, it may already have an "E" number.

One such example of an approved food additive is ascorbyl palmitate which is also known as E304 and is approved in the EU, the US, Australia and New Zealand.

Further examples include:

Tocopherols (E306) which have the following formula:

Wherein R4 and R6 are each independently FI or CH3; R5 is OFI; R7 is CFI3; and R8 is a Ci6 branched chain alkyl group;

Propyl gallate (E310):

Wherein R13 is a propyl group;

Tertiary butylhydroquinone (E319):

Wherein R2 is a tertiary butyl group and R3 is H; Butylated hydroxyanisole (E320):

Wherein R9 is a tertiary butyl group and R10 is H; and Butylated hydroxytoluene (E321):

Wherein R11 and R12 are each independently a tertiary butyl group.

The CBD may be present in the formulation in an amount of lOmg/ml to 300mg/ml. The lower limit on the amount of CBD in the formulation may be 15mg/ml, 20mg/ml, 25mg/ml, 30mg/ml, 35mg/ml. 40mg/ml, 45mg/ml or 50mg/ml. The upper limit on the amount of CBD present in the formulation may be 250mg/ml, 200mg/ml or 150mg/ml.

The amount of the stabiliser present in the formulation may be 0.5% to 5% by weight of the CBD content. For example, the stabiliser may be present in an amount of 0.5% to 2% by weight or 0.5 to 1.5% by weight of the CBD present in the formulation.

In other words, the ratio (weight/ml) of CBD to stabiliser in the formulation may be 200:1 to 50:1. In certain embodiments of the invention, the stabiliser may be present in the formulation in an amount of 0.05mg/ml to 5mg/ml.

The liquid carrier may include one or more glyceride compounds, suitably one or more plant-derived glyceride compounds. Glyceride compounds are often present in E-cigarette liquid formulations.

The formulation may contain nicotine. In an embodiment of the invention, the CBD is intended to replace at least some of the nicotine. Accordingly, the formulation may contain less nicotine than would otherwise be present in an E-cigarette formulation.

Formulations according to the invention may be used to wean users away from nicotine. Accordingly, a number of formulations may be available which contain a decreasing amount of nicotine. Thus, there may be provided a first formulation which contains CBD and a first amount

of nicotine, and a second formulation which contains CBD and a second amount of nicotine, wherein the second amount of nicotine is less than the first amount of nicotine. Optionally, a third formulation may be provided, wherein the third formulation contains CBD and a third amount of nicotine, wherein the third amount of nicotine is less than the second amount of nicotine. Such formulations may be available separately or they may form part of a kit. Thus, an aspect of the invention provides a kit containing a first formulation which contains CBD and a first amount of nicotine and a second formulation which contains CBD and a second amount of nicotine, wherein the second amount of nicotine is less than the first amount of nicotine. In an embodiment of this aspect of the invention, there is provided a kit which further includes a third formulation which contains CBD and a third amount of nicotine, wherein and the third amount of nicotine is less than the second amount of nicotine. In this aspect of the invention, the formulations are as defined herein.

The amount of nicotine present in the formulation may be 0 to 50mg/ml. Thus, no nicotine may be present in the formulation or, where present, it may be present in an amount of for example 5 to 40mg/ml, such as 10 to 30mg/ml.

The formulation may further comprise a flavouring agent. Such flavouring agents are common in the field of E-cigarette liquid formulations. Additionally or alternatively, the formulation may include a scent agent which releases a desired scent when the liquid is heated.

On the basis that there are numerous legal restrictions associated with tetrahydrocannabinol (THC), the formulation is suitably free from THC. A further aspect of the invention provides an e-cigarette liquid formulation (sometimes referred to as an e-cigarette liquid or simply and e-liquid) which comprises a liquid formulation as defined hereinabove.

Examples:

Comparative Example 1 A 20% w/v solution of CBD in propylene glycol with no stabiliser was prepared by dissolving 2g of CBD in 8ml of propylene glycol. The solution was placed in an open glass vial and monitored over a period of time. The colour of the solution was monitored during this time and the results are set out below:

It is believed that the colouration of the solution was due to the presence of an oxidised species of the CBD, wherein the CBD was being oxidised by the propylene glycol solvent. The oxidised species is thought to be a quinone derivative of CBD.

Comparative Example 2 A 5% w/v solution of CBD was prepared having the following formula: 2.5ml of the 20% w/v CBD solution of Comparative Example 1 3ml vegetable glycerine 4.1ml propylene glycol 0.4 ml menthol solution (200mg menthol in 1ml propylene glycol)

The solution was placed in an open glass vial and monitored over a period of time. The colour of the solution was monitored during this time and the results are set out below:

Example 1 A stabilised CBD solution was prepared by adding 0.2% w/v butylated hydroxyanisole (BHA) to the solution of Comparative Example 1 (2g CBD and 20mg BHA in 8ml propylene glycol). The solution was placed in an open glass vial and monitored over a period of time. The colour of the solution was monitored during this time and the results are set out below:

As can be seen, the rate of oxidation of the CBD in solution is significantly slowed by the addition of the BHA.

Example 2 A stabilised CBD solution was prepared by adding 0.05% w/v 6-O-palmitoyl-L-ascorbic acid (6-0-AP) to the solution of Comparative Example 1 (2g CBD and 5mg 6-O-AP in 8ml propylene glycol). The solution was placed in an open glass vial and monitored over a period of time. The colour of the solution was monitored during this time and the results are set out below:

Example 3 A stabilised CBD solution was prepared by adding 0.2% w/v 6-O-palmitoyl-L-ascorbic acid (6-O-AP) to the solution of Comparative Example 1 (2g CBD and 20mg 6-O-AP in 8ml propylene glycol). The solution was placed in an open glass vial and monitored over a period of time. The colour of the solution was monitored during this time and the results are set out below:

Example 4

A stabilised CBD solution was prepared by adding 0.05% w/v 6-O-AP to the solution of Comparative Example 2 to provide a solution having the following formulation: 2.5ml of the 20% w/v CBD solution of Example 3 (2g CBD and 20mg 6-O-AP in 8ml propylene glycol) 3ml vegetable glycerine 4.1ml propylene glycol 0.4 ml menthol solution (200mg menthol in 1ml propylene glycol)

It can be seen that the addition of a stabiliser as defined herein can reduce, slow down or prevent the oxidation of a solution of CBD in propylene glycol.

Claims

Claims:

1. A liquid formulation comprising cannabidiol, a stabiliser and a liquid carrier, wherein the liquid carrier includes propylene glycol, and the stabiliser comprises a head portion and a tail portion, wherein the head portion includes one or more reducing moieties and the tail portion comprises a C3-C20 straight or branched aliphatic chain.

2. A liquid formulation according to Claim 1, wherein the head portion includes a hydroxy substituted 5- or 6-membered carbocyclic or heterocyclic ring

3. A liquid formulation according to Claim 1, wherein the head portion of the stabiliser is derived from ascorbic acid, hydroquinone, hydroxychromane, hydroxyanisole, hydroxytoluene or gallic acid.

4. A liquid formulation according to any of Claims 1 to 3, wherein the aliphatic tail is directly bonded to the head portion or is bonded via a linker group selected from -0-, -0(0)C-, -C(0)-, -N(H)C(0)- and -N(H)-.

5. A liquid formulation according to Claim 1, wherein the stabiliser comprises a head group derived from ascorbic acid, a tail group which is a C6-C20 straight or branched aliphatic chain, and the tail group is connected to the head group via a carboxylate linker group.

6. A liquid formulation according to Claim 5, wherein the stabiliser is an ascorbate ester of a C7-C20 long chain acid.

7. A liquid formulation according to Claim 6, wherein the stabiliser is an ascorbate ester of palmitic acid.

8. A liquid formulation according to any of Claims 1 to 7, wherein the cannabidiol is present in the formulation in an amount of lOmg/ml to 300mg/ml.

9. A liquid formulation according to Claim 8, wherein the cannabidiol is present in an amount of 30mg/ml to 250mg/ml.

10. A liquid formulation according to Claim 9, wherein the cannabidiol is present in an amount of 50mg/ml to 200mg/ml.

11. A liquid formulation according to any of Claims 1 to 10, wherein the stabiliser is present in an amount of 0.05mg/ml to 5mg/ml

12. A liquid formulation according to any of Claims 1 to 11, wherein the ratio of cannabidiol to stabiliser in the mixture is 200:1 to 50:1.

13. A liquid formulation according to any of Claims 1 to 12, wherein the liquid carrier further includes one or more glyceride compounds.

14. A liquid formulation according to Claim 13, wherein the or each glyceride compound is derived from a plant source.

15. A liquid formulation according to any of Claims 1 to 14, wherein the formulation further includes nicotine.

16. A liquid formulation according to any of Claims 1 to 15, wherein the formulation further includes a flavouring agent and/or a scent agent.

17. A liquid formulation according to any of Claims 1 to 16, wherein the formulation is substantially free from tetrahydrocannabinol (THC).

18. An e-cigarette liquid comprising a liquid formulation according to any of Claims 1 to 17.